Global Health Challenges: Mpox Outbreaks and Medical Innovations

Recent health news highlights the UN's request for $18.5 million to combat mpox in Africa, Eli Lilly's weight-loss drug's efficacy in reducing diabetes risk, and the ruling out of a suspected mpox case in Argentina. Additionally, reports cover a deadly blast at an Indian pharma factory, and U.S. lawmakers' concerns over clinical trials in China.

In the realm of global health, urgent issues continue to command attention. The United Nation's International Organisation for Migration (IOM) has appealed for $18.5 million in assistance to combat the mpox outbreak affecting East and Southern Africa. This funding aims to provide critical health care services to vulnerable populations impacted by the crisis.

Eli Lilly has announced that its weight-loss drug, Zepbound, has significantly reduced the risk of developing type 2 diabetes among overweight or obese pre-diabetic adults, following three years of weekly injections. This news has positively impacted the company's stock, which saw a 4.4% increase.

Meanwhile, health authorities in Argentina have ruled out a suspected mpox case on a quarantined grains cargo ship, providing some relief amidst ongoing concerns about the spread of the virus.

(With inputs from agencies.)